BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld Asia
Home
» Diamyd Shares Fall On News Of Diabetes Trial Debacle
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Diamyd Shares Fall On News Of Diabetes Trial Debacle
June 20, 2007
By
Cormac Sheridan
No Comments
Diamyd Medical AB lost around 40 percent of its value Monday on news that it had to jettison a Phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes.(BioWorld International)
BioWorld Asia